Product image of Levosimendan Stada (Levosimendan) supplied by GNH India

Levosimendan Stada

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Stada (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer and inodilator presented as an intravenous solution for intravenous administration. It enhances cardiac contractility without increasing intracellular calcium and provides vasodilation, making it useful for patients experiencing acute decompensated heart failure where rapid hemodynamic support is required.

GNH India supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levosimendan is used in the management of heart failure syndromes where contractility support is needed.
  • Acute decompensated heart failure: improves cardiac output and relieves symptoms of low perfusion.
  • Severe chronic heart failure (when conventional therapy is insufficient): provides inotropic support to stabilize hemodynamics.
  • Low cardiac output syndrome after cardiac surgery: helps maintain systemic circulation during the postoperative period.

How It Works

  • Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation. These combined actions produce a positive inotropic effect together with reduced afterload, supporting cardiac output in heart failure patients.

Side Effects

Levosimendan may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypotension: transient drop in blood pressure.
  • Nausea: occasional gastrointestinal upset.
  • Tachycardia: increased heart rate.

Serious or Rare Side Effects

  • Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
  • Severe hypotension: marked blood pressure fall requiring intervention.
  • Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.

Precautions & Warnings

  • When using Levosimendan, clinicians should consider several safety measures.
  • Monitor blood pressure: watch for hypotension, especially in patients on other vasodilators.
  • Assess cardiac rhythm: observe for arrhythmias during infusion.
  • Evaluate renal function: adjust therapy if severe impairment is present.
  • Avoid concurrent strong CYP3A4 inhibitors: may increase plasma concentrations.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Levosimendan can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise levosimendan levels.
  • Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.
  • Potent vasodilators (e.g., nitroglycerin): can cause severe hypotension.

Moderate Interactions (Monitor Closely)

  • Diuretics: may potentiate electrolyte shifts.
  • Beta‑blockers: may blunt desired inotropic response.
  • ACE inhibitors or ARBs: monitor blood pressure and renal function.

Frequently Asked Questions

Levosimendan Stada is an intravenous formulation of levosimendan, a calcium sensitizer and inodilator indicated for the rapid treatment of acute decompensated heart failure and related low‑output cardiac conditions where immediate hemodynamic support is required.

Levosimendan increases the sensitivity of cardiac troponin C to calcium, producing a stronger contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac afterload, together improving overall cardiac output.

The dosage and infusion rate of Levosimendan Stada are determined by the prescribing clinician based on the patient’s clinical status, weight, and response. The prescriber sets the exact regimen, and it should be administered under close medical supervision.

Safety data for levosimendan during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility without increasing intracellular calcium, reducing the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that can be advantageous in certain heart‑failure patients.

Levosimendan Stada should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight and extreme temperatures to maintain stability before preparation for intravenous use.

Levosimendan Stada is given as an intravenous infusion. The preparation is added to a compatible infusion fluid and administered over a prescribed period, typically under continuous cardiac monitoring in a hospital setting.

The most serious risks include severe hypotension, ventricular arrhythmias and myocardial ischemia. These events require immediate medical attention and close monitoring during and after the infusion.

Patients with known hypersensitivity to levosimendan or any excipients, those with uncontrolled severe hypotension, recent myocardial infarction, or significant ventricular arrhythmias should not receive Levosimendan Stada unless a specialist determines that benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT